Survival rates at 5 years · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · People with advanced non‐small cell lung cancer
Epidermal growth factor showed no clear difference in overall survival compared with best supportive care (low certainty).
1 finding from 1 review
Progression‐free survival · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: at least one serious adverse event · People with advanced non‐small cell lung cancer
Epidermal growth factor showed no clear difference in participants with at least one serious adverse event compared with best supportive care (low certainty).
1 finding from 1 review
Change in eGFR · preventing the progression of CKD
1 finding from 1 review
Serious adverse events ( · preventing the progression of CKD
Metformin showed no clear difference in serious adverse events ( compared with active control (moderate certainty).
1 finding from 1 review
Withdrew due to intolerance ( · preventing the progression of CKD
Metformin showed no clear difference in withdrew due to intolerance ( compared with active control (moderate certainty).
1 finding from 1 review
Dosing and tolerance ( · preventing the progression of CKD
1 finding from 1 review
Kidney failure · preventing the progression of CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
UACR (% change) ( · preventing the progression of CKD
1 finding from 1 review
All‐cause death ( · preventing the progression of CKD
It is very uncertain whether metformin changes all‐cause death ( compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events ( · preventing the progression of CKD
Metformin showed no clear difference in serious adverse events ( compared with placebo (moderate certainty).
1 finding from 1 review
Withdrew due to intolerance ( · preventing the progression of CKD
Metformin probably leads to higher withdrew due to intolerance ( compared with placebo (moderate certainty).
1 finding from 1 review
Dose tolerability ( · preventing the progression of CKD
1 finding from 1 review
Kidney failure · preventing the progression of CKD
It is very uncertain whether metformin changes kidney failure (median compared with placebo (very low certainty).
1 finding from 1 review
Change in proteinuria (1 year) · preventing the progression of CKD
1 finding from 1 review
Change in eGFR · preventing the progression of CKD
1 finding from 1 review
All‐cause death ( · preventing the progression of CKD
Metformin showed no clear difference in all‐cause death ( compared with active control (low certainty).
1 finding from 1 review
Anxiety · adolescents with asthma
1 finding from 1 review